Literature DB >> 28074074

IBD in 2016: Biologicals and biosimilars in IBD - the road to personalized treatment.

Krisztina B Gecse1, Péter L Lakatos1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28074074     DOI： 10.1038/nrgastro.2016.206

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

Authors:  Aurelien Amiot; Jean-Charles Grimaud; Laurent Peyrin-Biroulet; Jerome Filippi; Benjamin Pariente; Xavier Roblin; Anthony Buisson; Carmen Stefanescu; Caroline Trang-Poisson; Romain Altwegg; Philippe Marteau; Thibaud Vaysse; Anne Bourrier; Stephane Nancey; David Laharie; Matthieu Allez; Guillaume Savoye; Jacques Moreau; Charlotte Gagniere; Lucine Vuitton; Stephanie Viennot; Alexandre Aubourg; Anne-Laure Pelletier; Guillaume Bouguen; Vered Abitbol; Yoram Bouhnik
Journal:  Clin Gastroenterol Hepatol       Date:  2016-02-22       Impact factor: 11.382

Review 2.  Review article: loss of response to anti-TNF treatments in Crohn's disease.

Authors:  S Ben-Horin; Y Chowers
Journal:  Aliment Pharmacol Ther       Date:  2011-03-02       Impact factor: 8.171

3.  Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.

Authors:  Shomron Ben-Horin; Miri Yavzori; Itai Benhar; Ella Fudim; Orit Picard; Bella Ungar; SooYoung Lee; SungHwan Kim; Rami Eliakim; Yehuda Chowers
Journal:  Gut       Date:  2015-04-20       Impact factor: 23.059

4.  Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

Authors:  Julián Panés; Damián García-Olmo; Gert Van Assche; Jean Frederic Colombel; Walter Reinisch; Daniel C Baumgart; Axel Dignass; Maria Nachury; Marc Ferrante; Lili Kazemi-Shirazi; Jean C Grimaud; Fernando de la Portilla; Eran Goldin; Marie Paule Richard; Anne Leselbaum; Silvio Danese
Journal:  Lancet       Date:  2016-07-29       Impact factor: 79.321

5.  Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.

Authors:  Pauline Wils; Yoram Bouhnik; Pierre Michetti; Bernard Flourie; Hedia Brixi; Anne Bourrier; Matthieu Allez; Bernard Duclos; Jean-Charles Grimaud; Anthony Buisson; Aurélien Amiot; Mathurin Fumery; Xavier Roblin; Laurent Peyrin-Biroulet; Jérôme Filippi; Guillaume Bouguen; Vered Abitbol; Benoit Coffin; Marion Simon; David Laharie; Benjamin Pariente
Journal:  Clin Gastroenterol Hepatol       Date:  2015-09-30       Impact factor: 11.382

6.  The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study.

Authors:  Andres J Yarur; Anjali Jain; Daniel A Sussman; Jamie S Barkin; Maria A Quintero; Fred Princen; Richard Kirkland; Amar R Deshpande; Sharat Singh; Maria T Abreu
Journal:  Gut       Date:  2015-02-10       Impact factor: 23.059

7.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.

Authors:  Johannan F Brandse; Gijs R van den Brink; Manon E Wildenberg; Desiree van der Kleij; Theo Rispens; Jeroen M Jansen; Ron A Mathôt; Cyriel Y Ponsioen; Mark Löwenberg; Geert R A M D'Haens
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

8.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Authors:  Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

9.  Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

Authors:  Krisztina B Gecse; Barbara D Lovász; Klaudia Farkas; János Banai; László Bene; Beáta Gasztonyi; Petra Anna Golovics; Tünde Kristóf; László Lakatos; Ágnes Anna Csontos; Márk Juhász; Ferenc Nagy; Károly Palatka; Mária Papp; Árpád Patai; Lilla Lakner; Ágnes Salamon; Tamás Szamosi; Zoltán Szepes; Gábor T Tóth; Áron Vincze; Balázs Szalay; Tamás Molnár; Péter L Lakatos
Journal:  J Crohns Colitis       Date:  2015-12-10       Impact factor: 9.071
  9 in total
  6 in total

Review 1.  Vaccination in the Elderly and IBD.

Authors:  Anthony J Choi; Preston Atteberry; Dana J Lukin
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 2.  Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases.

Authors:  Atsunori Tsuchiya; Yuichi Kojima; Shunzo Ikarashi; Satoshi Seino; Yusuke Watanabe; Yuzo Kawata; Shuji Terai
Journal:  Inflamm Regen       Date:  2017-07-03

3.  Caffeic acid phenethyl ester is protective in experimental ulcerative colitis via reduction in levels of pro-inflammatory mediators and enhancement of epithelial barrier function.

Authors:  Mohammed N Khan; Majella E Lane; Paul A McCarron; Murtaza M Tambuwala
Journal:  Inflammopharmacology       Date:  2017-05-20       Impact factor: 4.473

4.  IGF-1C hydrogel improves the therapeutic effects of MSCs on colitis in mice through PGE2-mediated M2 macrophage polarization.

Authors:  Xiaocang Cao; Liyun Duan; Huixing Hou; Yue Liu; Shang Chen; Shuaiqiang Zhang; Yuanyuan Liu; Chen Wang; Xin Qi; Na Liu; Zhibo Han; Dekui Zhang; Zhong-Chao Han; Zhikun Guo; Qiang Zhao; Zongjin Li
Journal:  Theranostics       Date:  2020-06-19       Impact factor: 11.556

Review 5.  Modulating T Cell Responses via Autophagy: The Intrinsic Influence Controlling the Function of Both Antigen-Presenting Cells and T Cells.

Authors:  Seth D Merkley; Cameron J Chock; Xuexian O Yang; James Harris; Eliseo F Castillo
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

6.  Identification of anti-inflammatory compounds from Zhongjing formulae by knowledge mining and high-content screening in a zebrafish model of inflammatory bowel diseases.

Authors:  Yunru Yu; Jing Chen; Xiaohui Zhang; Yingchao Wang; Shufang Wang; Lu Zhao; Yi Wang
Journal:  Chin Med       Date:  2021-05-31       Impact factor: 5.455
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.